Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Trends in Immunology|May 18, 2017
Mechanisms of Immune Tolerance in Leukemia and LymphomaEmily K Curran, James Godfrey, Justin Kline
Journal of Neuro-Oncology|April 28, 2009
Do children and adults differ in survival from medulloblastoma? A study from the SEER registryEmily K Curran, Gem M Le, Kristin L Sainani, et al.
Pediatric Blood & Cancer|November 14, 2008
Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results RegistryEmily K Curran, Kristin L Sainani, Gem M Le, et al.
Journal of Pediatric Hematology/Oncology|November 6, 2009
Medulloblastoma incidence has not changed over time: a CBTRUS studySonia Partap, Emily K Curran, Jennifer M Propp, et al.
Journal of Geriatric Oncology|January 30, 2014
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapyRonald J Maggiore, Emily K Curran, Mary Ellyn Witt, et al.
American Journal of Hematology|October 11, 2025
Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel RecommendationsIbrahim Aldoss, Amir Ali, Ryan D Cassaday, et al.
Cancer Control : Journal of the Moffitt Cancer Center|July 20, 2026
Adolescents and Young Adults With Acute Lymphoblastic Leukemia: Qualitative Barriers and Facilitators to Guideline-Concordant CareAllison C Grimes, Julie A Wolfson, Charlotte L Kerber, et al.
Haematologica|November 6, 2025
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Pageof 1